Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial
Cathrien S. Tromp-van Driel, Christa van Schaik - van de Mheen, Hedwig M. Blommestein, Aart Beeker et al.
Citations
1 citations
Journal
JNCI Journal of the National Cancer Institute
Topics
Advanced Breast Cancer Therapies
Field-Weighted Citation Impact (FWCI)
1.52
article
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial
Cathrien S. Tromp-van Driel, Christa van Schaik - van de Mheen, Hedwig M. Blommestein, Aart Beeker, Suzan Vrijaldenhoven, Vincent van der Noort, Gabe S. Sonke, Joan B. Heijns, A. Elise van Leeuwen‐Stok, Quirine C. van Rossum‐Schornagel, Agnes Jager, Karin Beelen, Lisanne C. Hamming, E. van den Pol, Cristina Guerrero Páez, Annemiek van Ommen‐Nijhof, Noor Wortelboer, Inge R. Konings, Paul C. de Jong, Jolien Tol, Aafke H. Honkoop, Seamus Kent
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
JNCI Journal of the National Cancer InstituteVol. 118(3)
Institutions
Breast Cancer Research Foundation (US), Dutch Cancer Society (NL), Gelre Hospitals (NL), Medisch Centrum Leeuwarden (NL), The Netherlands Cancer Institute (NL), Spaarne Ziekenhuis (NL), Northwest Hospital (US), St. Antonius Ziekenhuis (NL), Amphia Ziekenhuis (NL), Borstkankervereniging Nederland (NL), Oncode Institute (NL), Netherlands Comprehensive Cancer Organisation (NL), Isala (NL), Erasmus MC Cancer Institute (NL), Franciscus Vlietland (NL), Amsterdam University Medical Centers (NL), Rijnstate Hospital (NL), Meander Medisch Centrum (NL), Jeroen Bosch Ziekenhuis (NL), University of Amsterdam (NL), Erasmus University Rotterdam (NL)